

VIACELL INC  
Form 8-K  
August 09, 2007

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
FORM 8-K  
CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934  
Date of report (Date of earliest event reported): August 9, 2007  
VIACELL, INC.  
(Exact name of registrant as specified in its charter)**

Delaware	000-51110	04-3244816
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)
	245 First Street, Cambridge, Massachusetts 02142 (Address of Principal Executive Offices) (Zip Code)	

Registrant's telephone number, including area code: (617) 914-3400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 2.02. Results of Operations and Financial Condition

Item 9.01 Financial Statements and Exhibits.

SIGNATURE

EXHIBIT LIST

Press Release dated August 9, 2007

---

**Table of Contents**

**Item 2.02. Results of Operations and Financial Condition**

On August 9, 2007, ViaCell, Inc. issued a press release announcing its results of operations and financial condition for the second quarter of 2007.

The information furnished herewith pursuant to Item 2.02 of this Current Report shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act ), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

99.1 Press release issued by ViaCell, Inc. dated August 9, 2007.

---

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VIACELL, INC.

Date: August 9, 2007

By: /s/ John F. Thero  
Name: John F. Thero  
Title: Senior Vice President, Finance  
and Chief Financial Officer

---

**Table of Contents**

**EXHIBIT LIST**

<b>Exhibit</b>	<b>Description</b>
99.1	Press release issued by ViaCell, Inc. dated August 9, 2007